Study data convince Lundbeck to push new migraine drug forward

BioPharma Dive·Jun 5

This story is reported by BioPharma Dive. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

Lundbeck Presents New VYEPTI® (eptinezumab-jjmr) and Bocunebart Migraine Data at the American Headache Society 68th Annual Scientific Meeting

Yahoo Finance·Jun 4

2

Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

Yahoo Finance·Jun 4

3

A new Westlake-backed biotech takes aim at migraines

BioPharma Dive·Jun 17

4

Research director on a changed Lundbeck: "We are no more than six years old"

medwatch.com·Aug 4

5

Vedana Therapeutics Launches With $46 Million Series A Financing to Advance Next-Generation Migraine Therapies

Yahoo Finance·Jun 17

6

Oblique Therapeutics today announced that Dr. Jan Lundberg has joined the company as Scientific Advisor

Yahoo Finance·May 8

7

Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

Yahoo Finance·Feb 4